Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Sort by Random

Display 30 Products per page

Company Analysis: Seagen

$3,000.00

PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
2016 M&A Outlook

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds.
September 28, 2016
Find out more
Company Analysis: Bayer

$3,000.00

PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more
Company Analysis: Takeda

$3,000.00

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
Q2 2016 Earnings Previews

$3,000.00

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.
September 28, 2016
Find out more
Company Analysis : AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.
July 15, 2020
Find out more
Company Analysis: Vertex

$3,000.00

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: BioMarin

$3,000.00

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
M&A Outlook 2018

$3,000.00

PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
April 24, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *